Scott Kathleen D.

Director at DRMA; Chief Financial Officer at SPRY

Sold, on record
$1.3M
Dollars the filings state
Form 4 sales
5
Latest Jun 16, 2026
Form 144 notices
4
Proposed sales
Companies
2
Filed as an executive or holder

Companies

  • DRMADermata Therapeutics, Inc.Director
  • SPRYARS Pharmaceuticals, Inc.Chief Financial Officer

Sales by reason

3
Routine
0
Plan not stated
0
No plan
2
Unusual
Stacked: routine sales under a plan, sales whose filing does not state a plan, sales with no plan, and unusual sales.

Form 4 sales per month, every sale on record.

Sales chart range

Sales by company

Shares sold, every Form 4 sale on record.

Timeline

  1. Jun 16, 2026Unusual

    DRMA

    Sold 100% of their holdings

    $1311 shares at $1.19

    Filed Jun 16, 2026Form 4

  2. Aug 21, 2025Routine

    SPRY

    Sold 55.5% of their holdings

    $188k12,500 shares at $15.00

    Filed Aug 22, 2025Form 4

  3. Aug 21, 2025Notice

    SPRY

    Filed a notice to sell 12,500 shares

    $188k12,500 shares

    Filed Aug 21, 2025Form 144

  4. May 20, 2025Unusual

    SPRY

    Sold 87.1% of their holdings

    $705k50,000 shares at $14.10

    Filed May 22, 2025Form 4

  5. May 20, 2025Notice

    SPRY

    Filed a notice to sell 50,000 shares

    $705k50,000 shares

    Filed May 20, 2025Form 144

  6. Oct 16, 2024Routine

    SPRY

    Sold 71.6% of their holdings

    $200k12,500 shares at $16.00

    Filed Oct 17, 2024Form 4

  7. Oct 16, 2024Notice

    SPRY

    Filed a notice to sell 12,500 shares

    $200k12,500 shares

    Filed Oct 16, 2024Form 144

  8. Aug 20, 2024Routine

    SPRY

    Sold 48.6% of their holdings

    $200k12,500 shares at $16.00

    Filed Aug 21, 2024Form 4

  9. Aug 20, 2024Notice

    SPRY

    Filed a notice to sell 12,500 shares

    $200k12,500 shares

    Filed Aug 20, 2024Form 144

9 of 9

Every transaction

Every transaction on a Form 4 or Form 5 by Scott Kathleen D.
TradedFiledStockRoleWhatAmountPriceValueHeld afterSource
Jun 16, 2026Jun 16, 2026DRMADirectorSold11$1.19$130SEC
Jan 2, 2026Jan 5, 2026SPRYChief Financial OfficerAwardedStock option (right to buy)240,000240,000SEC
Jan 2, 2026Jan 6, 2026DRMADirectorAwardedStock Option (Right to Buy)2,5002,500SEC
Aug 21, 2025Aug 22, 2025SPRYChief Financial OfficerSold12,500$15.00$188k10,042SEC
Aug 21, 2025Aug 22, 2025SPRYChief Financial OfficerExercised or settledStock Option (Right to Buy)12,500739,830SEC
Aug 21, 2025Aug 22, 2025SPRYChief Financial OfficerExercised options12,500$1.50$19k22,542SEC
May 20, 2025May 22, 2025SPRYChief Financial OfficerSold50,000$14.10$705k7,424SEC
May 20, 2025May 22, 2025SPRYChief Financial OfficerExercised or settledStock Option (Right to Buy)50,000752,330SEC
May 20, 2025May 22, 2025SPRYChief Financial OfficerExercised options50,000$1.50$75k57,424SEC
Jan 13, 2025Jan 14, 2025DRMADirectorAwardedStock Option (Right to Buy)5,0005,000SEC
Jan 2, 2025Jan 3, 2025SPRYChief Financial OfficerAwardedStock option (right to buy)176,700176,700SEC
Dec 6, 2024Dec 10, 2024NKGNDirectorAwardedStock Option (right to buy)800,000500,000SEC
Oct 16, 2024Oct 17, 2024SPRYChief Financial OfficerSold12,500$16.00$200k4,949SEC
Oct 16, 2024Oct 17, 2024SPRYChief Financial OfficerExercised or settledStock Option (Right to Buy)12,500802,330SEC
Oct 16, 2024Oct 17, 2024SPRYChief Financial OfficerExercised options12,500$1.50$19k17,449SEC
Aug 20, 2024Aug 21, 2024SPRYChief Financial OfficerSold12,500$16.00$200k13,199SEC
Aug 20, 2024Aug 21, 2024SPRYChief Financial OfficerExercised or settledStock Option (Right to Buy)12,500814,830SEC
Aug 20, 2024Aug 21, 2024SPRYChief Financial OfficerExercised options12,500$1.50$19k25,699SEC
Feb 12, 2024Feb 14, 2024NKGNDirectorAwardedStock Option (right to buy)300,000300,000SEC
Jan 4, 2024Jan 5, 2024DRMADirectorAwardedStock Option (Right to Buy)10,00010,000SEC
Jan 2, 2024Jan 4, 2024SPRYChief Financial OfficerAwardedStock option (right to buy)200,000200,000SEC
Jan 3, 2023Jan 5, 2023SPRYChief Financial OfficerAwardedStock option (right to buy)50,00050,000SEC
Nov 29, 2022Dec 1, 2022SPRYChief Financial OfficerBought8,250$6.24$51k8,250SEC
Nov 8, 2022Nov 10, 2022SPRYChief Financial OfficerAwardedEmployee Stock Option (right to buy)827,330827,330SEC
Oct 6, 2022Oct 7, 2022DRMADirectorAwarded11,35927,145SEC
Jul 7, 2022Jul 8, 2022DRMADirectorAwarded9,96015,786SEC
Apr 7, 2022Apr 8, 2022DRMADirectorAwarded5,8265,826SEC
Jan 3, 2022Jan 5, 2022DRMADirectorAwardedStock Option (right to buy)5,0005,000SEC
Aug 17, 2021Aug 17, 2021DRMADirectorAwardedStock Option (right to Buy)10,00010,000SEC
Nov 18, 2019Nov 19, 2019Conatus Pharmaceuticals IncDirectorAwardedStock Option (Right to Buy)30,00030,000SEC

Sales and notices (9)

Form 144 notices and Form 4 sales by Scott Kathleen D.
Source
Jun 16, 2026Jun 16, 2026DRMADirectorForm 4 sale11$13100.0%UnusualSEC
Aug 21, 2025Aug 22, 2025SPRYChief Financial OfficerForm 4 sale12,500$188k55.5%RoutineSEC
Aug 21, 2025Aug 21, 2025SPRYChief Financial OfficerForm 144 notice12,500$188kNoticeSEC
May 20, 2025May 22, 2025SPRYChief Financial OfficerForm 4 sale50,000$705k87.1%UnusualSEC
May 20, 2025May 20, 2025SPRYChief Financial OfficerForm 144 notice50,000$705kNoticeSEC
Oct 16, 2024Oct 17, 2024SPRYChief Financial OfficerForm 4 sale12,500$200k71.6%RoutineSEC
Oct 16, 2024Oct 16, 2024SPRYChief Financial OfficerForm 144 notice12,500$200kNoticeSEC
Aug 20, 2024Aug 21, 2024SPRYChief Financial OfficerForm 4 sale12,500$200k48.6%RoutineSEC
Aug 20, 2024Aug 20, 2024SPRYChief Financial OfficerForm 144 notice12,500$200kNoticeSEC